Report cover image

Contract Development and Manufacturing Organization Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034

Publisher Fortune Business Insights Pvt. Ltd.
Published Mar 01, 2026
Length 150 Pages
SKU # FOB21036904

Description

Growth Factors of Contract Development and Manufacturing Organization (CDMO) Market

The global Contract Development and Manufacturing Organization (CDMO) market has emerged as a critical backbone of the pharmaceutical and biotechnology industries, enabling companies to accelerate drug development while optimizing operational efficiency. According to the report timeline, the global CDMO market size was valued at USD 255.01 billion in 2025. Driven by increasing outsourcing trends and rising complexity of drug pipelines, the market is projected to grow to USD 273.40 billion in 2026. Over the long-term forecast period, sustained demand for outsourced development, manufacturing, and clinical services is expected to propel the market to USD 580.72 billion by 2034.

CDMOs provide end-to-end services covering drug discovery support, formulation development, clinical trial material production, commercial-scale manufacturing, and packaging. The growing focus of pharmaceutical and biotechnology companies on core competencies, combined with limited in-house manufacturing capacity—particularly among small and mid-sized firms—continues to accelerate reliance on CDMO partners. In addition, the surge in biologics, biosimilars, cell and gene therapies, and personalized medicines has further strengthened the strategic importance of CDMOs across the global healthcare value chain.

Market Dynamics

A primary driver of CDMO market growth is the increasing outsourcing of clinical trials and medicines production. Outsourcing enables pharmaceutical companies to significantly reduce capital expenditure on infrastructure, workforce, and compliance while gaining access to specialized expertise and advanced manufacturing technologies. CDMOs also support faster time-to-market, which is critical in competitive therapeutic areas such as oncology, neurology, and rare diseases.

Another important growth catalyst is the rising investment in research and development of advanced therapeutics. Governments and healthcare agencies are supporting innovation through funding programs and clinical trial incentives, which indirectly benefit CDMOs by increasing trial volumes and manufacturing demand. Strategic collaborations between CDMOs and pharma-biotech companies are becoming more frequent, allowing seamless progression from early development to commercial production.

However, the market faces restraints due to stringent regulatory requirements across regions. CDMOs must comply with Good Manufacturing Practices (GMP), data integrity norms, and evolving regulatory frameworks set by agencies such as the U.S. FDA and the European Medicines Agency. Regulatory delays or compliance issues at third-party manufacturing sites can disrupt development timelines and impact revenue generation for both sponsors and CDMOs.

Market Opportunities and Challenges

The rising cost of drug development and manufacturing presents strong opportunities for CDMOs. As pharmaceutical companies face inflationary pressures, supply chain disruptions, and workforce shortages, outsourcing to specialized CDMOs becomes an economically attractive option. Increasing collaborations and long-term partnerships are expected to create stable revenue streams for CDMO providers.

At the same time, the market is challenged by fragmentation and intense competition, with the presence of numerous small and mid-sized CDMOs offering overlapping services. Additionally, the shortage of skilled professionals in biologics manufacturing, regulatory affairs, and quality assurance poses operational challenges, particularly for advanced therapy manufacturing.

Market Trends

A key trend shaping the CDMO industry is the growing wave of mergers and acquisitions. Consolidation enables CDMOs to expand service portfolios, enhance geographic presence, and offer integrated end-to-end solutions. Another major trend is the shift toward full-service CDMOs, capable of supporting clients from discovery through commercialization, reducing technology transfer risks and regulatory complexity.

Digitalization and smart manufacturing are also gaining traction, with CDMOs adopting automation, artificial intelligence, and data-driven process optimization to improve efficiency and compliance. Sustainability initiatives, including green chemistry and energy-efficient manufacturing, are increasingly influencing client selection criteria.

Segmentation Insights

By service, the Contract Manufacturing Organization (CMO) segment dominated the market in 2024, supported by high demand for API and finished dosage form manufacturing. The Contract Research Organization (CRO) segment is expected to grow at a faster pace due to increasing outsourcing of clinical trial management, early-phase development, and regulatory support.

Regional Outlook

North America dominated the CDMO market with a 38.50% share in 2025, supported by a strong ecosystem of established CDMOs, a high number of clinical trials, and robust pharma-biotech partnerships. Europe remains the second-largest market, driven by regulatory harmonization and active participation in global biotech conferences. Asia Pacific is emerging as a high-growth region due to expanding biopharmaceutical investments, cost advantages, and supportive government policies in countries such as China, India, and Japan.

Competitive Landscape

The global CDMO market features prominent players such as IQVIA, ICON plc, Lonza, Thermo Fisher Scientific Inc., and Vetter. These companies focus on strategic partnerships, service expansion, and acquisitions to strengthen market presence.

Conclusion

The global Contract Development and Manufacturing Organization (CDMO) market is entering a phase of sustained and structurally strong growth, underpinned by the pharmaceutical and biotechnology industry’s increasing reliance on outsourcing. With a market size of USD 255.01 billion in 2025, the expansion to USD 273.40 billion in 2026 reflects the accelerating shift toward externalized drug development, clinical trial support, and large-scale manufacturing. The long-term projection of USD 580.72 billion by 2034 highlights the critical and expanding role of CDMOs in managing complex drug pipelines, particularly in biologics, biosimilars, and advanced therapies.

Rising R&D intensity, growing development and manufacturing costs, and limited in-house capabilities—especially among small and mid-sized pharmaceutical companies—continue to strengthen demand for end-to-end CDMO services. At the same time, challenges such as stringent regulatory requirements, talent shortages, and market fragmentation require CDMO providers to invest continuously in compliance, workforce development, and technological innovation. Regional dominance by North America, combined with rapid growth in Asia Pacific and steady expansion in Europe, indicates a well-balanced global opportunity landscape. Overall, strictly aligned with the report years 2025, 2026, and 2034, the CDMO market is expected to remain a cornerstone of the global pharmaceutical supply chain, enabling faster innovation, scalability, and efficiency across drug development and commercialization.

ATTRIBUTE DETAILS

Study Period 2021–2034

Base Year 2025

Estimated Year 2026

Forecast Period 2026-2034

Historical Period 2021–2024

Growth Rate CAGR of 9.90% from 2026-2034

Unit Value (USD Billion)

Segmentation By Service

CMO
  • API Manufacturing
  • Finished Product Manufacturing
  • Solid Dosage Forms
  • Injectables
  • Others
  • Packaging
CRO
  • Early Phase Development Services
  • Chemistry, Manufacturing, and Controls (CMC)
  • Preclinical Service
  • Discovery
  • Clinical
  • Phase 1
  • Phase 2
  • Phase 3
  • Phase 4
  • Laboratory Service
  • Others
By Region

North America (By Service and Country)
  • U.S.
  • Canada
Europe (By Service and Country/Sub-Region)
  • U.K.
  • Germany
  • France
  • Spain
  • Italy
  • Scandinavia
  • Rest of Europe
Asia Pacific (By Service and Country/Sub-Region)
  • China
  • Japan
  • India
  • Australia & New Zealand
  • Rest of Asia Pacific
Rest of the World (By Service)

Please Note: It will take 2-3 business days to complete the report upon order confirmation.

Table of Contents

150 Pages
1. Introduction
1.1. Research Scope
1.2. Market Segmentation
1.3. Research Methodology
1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
3.1. Market Drivers
3.2. Market Restraints
3.3. Market Opportunities
3.4. Market Trends
4. Key Insights
4.1. Number of Clinical Trials Conducted by Key Countries/ Sub-Region, 2025
4.2. Overview: Start-ups and Innovations in the Contract Development and Manufacturing Organization (CDMO) Market
4.3. Overview on Outsourcing of R&D, by Key Pharmaceutical Companies
4.4. R&D Investments, by Key Pharmaceutical and Biotechnological Companies
4.5. Key Industry Developments (Mergers, Acquisitions, Partnerships, etc.)
4.6. Impact of COVID-19 on the Market
5. Global Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2021-2034
5.1. Market Analysis, Insights and Forecast – By Service
5.1.1. CMO
5.1.1.1. API Manufacturing
5.1.1.2. Finished Product Manufacturing
5.1.1.2.1. Solid Dosage Forms
5.1.1.2.2. Injectables
5.1.1.2.3. Others
5.1.1.3. Packaging
5.1.2. CRO
5.1.2.1. Early Phase Development Services
5.1.2.1.1. Chemistry, Manufacturing and Controls (CMC)
5.1.2.1.2. Preclinical Service
5.1.2.1.3. Discovery
5.1.2.2. Clinical
5.1.2.2.1. Phase 1
5.1.2.2.2. Phase 2
5.1.2.2.3. Phase 3
5.1.2.2.4. Phase 4
5.1.2.3. Laboratory Service
5.1.2.4. Others
5.2. Market Analysis, Insights and Forecast – By Region
5.2.1. North America
5.2.2. Europe
5.2.3. Asia Pacific
5.2.4. Rest of the World
6. North America Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2021-2034
6.1. Market Analysis, Insights and Forecast – By Service
6.1.1. CMO
6.1.1.1. API Manufacturing
6.1.1.2. Finished Product Manufacturing
6.1.1.2.1. Solid Dosage Forms
6.1.1.2.2. Injectables
6.1.1.2.3. Others
6.1.1.3. Packaging
6.1.2. CRO
6.1.2.1. Early Phase Development Services
6.1.2.1.1. Chemistry, Manufacturing and Controls (CMC)
6.1.2.1.2. Preclinical Service
6.1.2.1.3. Discovery
6.1.2.2. Clinical
6.1.2.2.1. Phase 1
6.1.2.2.2. Phase 2
6.1.2.2.3. Phase 3
6.1.2.2.4. Phase 4
6.1.2.3. Laboratory Service
6.1.2.4. Others
6.2. Market Analysis, Insights and Forecast – By Country
6.2.1. U.S.
6.2.2. Canada
7. Europe Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2021-2034
7.1. Market Analysis, Insights and Forecast – By Service
7.1.1. CMO
7.1.1.1. API Manufacturing
7.1.1.2. Finished Product Manufacturing
7.1.1.2.1. Solid Dosage Forms
7.1.1.2.2. Injectables
7.1.1.2.3. Others
7.1.1.3. Packaging
7.1.2. CRO
7.1.2.1. Early Phase Development Services
7.1.2.1.1. Chemistry, Manufacturing and Controls (CMC)
7.1.2.1.2. Preclinical Service
7.1.2.1.3. Discovery
7.1.2.2. Clinical
7.1.2.2.1. Phase 1
7.1.2.2.2. Phase 2
7.1.2.2.3. Phase 3
7.1.2.2.4. Phase 4
7.1.2.3. Laboratory Service
7.1.2.4. Others
7.2. Market Analysis, Insights and Forecast – By County/ Sub-region
7.2.1. Germany
7.2.2. U.K.
7.2.3. France
7.2.4. Italy
7.2.5. Spain
7.2.6. Scandinavia
7.2.7. Rest of Europe
8. Asia Pacific Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2021-2034
8.1. Market Analysis, Insights and Forecast – By Service
8.1.1. CMO
8.1.1.1. API Manufacturing
8.1.1.2. Finished Product Manufacturing
8.1.1.2.1. Solid Dosage Forms
8.1.1.2.2. Injectables
8.1.1.2.3. Others
8.1.1.3. Packaging
8.1.2. CRO
8.1.2.1. Early Phase Development Services
8.1.2.1.1. Chemistry, Manufacturing and Controls (CMC)
8.1.2.1.2. Preclinical Service
8.1.2.1.3. Discovery
8.1.2.2. Clinical
8.1.2.2.1. Phase 1
8.1.2.2.2. Phase 2
8.1.2.2.3. Phase 3
8.1.2.2.4. Phase 4
8.1.2.3. Laboratory Service
8.1.2.4. Others
8.2. Market Analysis, Insights and Forecast – By Country/ Sub-region
8.2.1. China
8.2.2. India
8.2.3. Japan
8.2.4. Australia & New Zealand
8.2.5. Rest of Asia Pacific
9. Rest of the World Contract Development and Manufacturing Organization (CDMO) Market Analysis, Insights and Forecast, 2021-2034
9.1. Market Analysis, Insights and Forecast – By Service
9.1.1. CMO
9.1.1.1. API Manufacturing
9.1.1.2. Finished Product Manufacturing
9.1.1.2.1. Solid Dosage Forms
9.1.1.2.2. Injectables
9.1.1.2.3. Others
9.1.1.3. Packaging
9.1.2. CRO
9.1.2.1. Early Phase Development Services
9.1.2.1.1. Chemistry, Manufacturing and Controls (CMC)
9.1.2.1.2. Preclinical Service
9.1.2.1.3. Discovery
9.1.2.2. Clinical
9.1.2.2.1. Phase 1
9.1.2.2.2. Phase 2
9.1.2.2.3. Phase 3
9.1.2.2.4. Phase 4
9.1.2.3. Laboratory Service
9.1.2.4. Others
10. Competitive Analysis
10.1. Global Market Share Analysis (2025)
10.2. Company Profiles
10.2.1. IQVIA
10.2.1.1. Overview
10.2.1.2. Products
10.2.1.3. Financials (Based on Availability)
10.2.1.4. Recent Developments
10.2.1.5. Strategies
10.2.1.6. SWOT,Etc.
10.2.2. ICON plc
10.2.2.1. Overview
10.2.2.2. Products
10.2.2.3. Financials (Based on Availability)
10.2.2.4. Recent Developments
10.2.2.5. Strategies
10.2.2.6. SWOT,Etc.
10.2.3. Syneos Health
10.2.3.1. Overview
10.2.3.2. Products
10.2.3.3. Financials (Based on Availability)
10.2.3.4. Recent Developments
10.2.3.5. Strategies
10.2.3.6. SWOT,Etc.
10.2.4. Vetter
10.2.4.1. Overview
10.2.4.2. Products
10.2.4.3. Financials (Based on Availability)
10.2.4.4. Recent Developments
10.2.4.5. Strategies
10.2.4.6. SWOT,Etc.
10.2.5. Parexel International (MA) Corporation
10.2.5.1. Overview
10.2.5.2. Products
10.2.5.3. Financials (Based on Availability)
10.2.5.4. Recent Developments
10.2.5.5. Strategies
10.2.5.6. SWOT,Etc.
10.2.6. Recipharm AB
10.2.6.1. Overview
10.2.6.2. Products
10.2.6.3. Financials (Based on Availability)
10.2.6.4. Recent Developments
10.2.6.5. Strategies
10.2.6.6. SWOT,Etc.
10.2.7. Curia Global, Inc.
10.2.7.1. Overview
10.2.7.2. Products
10.2.7.3. Financials (Based on Availability)
10.2.7.4. Recent Developments
10.2.7.5. Strategies
10.2.7.6. SWOT,Etc.
10.2.8. Thermo Fisher Scientific Inc.
10.2.8.1. Overview
10.2.8.2. Products
10.2.8.3. Financials (Based on Availability)
10.2.8.4. Recent Developments
10.2.8.5. Strategies
10.2.8.6. SWOT,Etc.
10.2.9. Unither
10.2.9.1. Overview
10.2.9.2. Products
10.2.9.3. Financials (Based on Availability)
10.2.9.4. Recent Developments
10.2.9.5. Strategies
10.2.9.6. SWOT,Etc.
10.2.10. DPT Laboratories, LTD.
10.2.10.1. Overview
10.2.10.2. Products
10.2.10.3. Financials (Based on Availability)
10.2.10.4. Recent Developments
10.2.10.5. Strategies
10.2.10.6. SWOT,Etc.
10.2.11. NextPharma Technologies
10.2.11.1. Overview
10.2.11.2. Products
10.2.11.3. Financials (Based on Availability)
10.2.11.4. Recent Developments
10.2.11.5. Strategies
10.2.11.6. SWOT,Etc.
10.2.12. Lonza
10.2.12.1. Overview
10.2.12.2. Products
10.2.12.3. Financials (Based on Availability)
10.2.12.4. Recent Developments
10.2.12.5. Strategies
10.2.12.6. SWOT,Etc.

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Request A Sample
Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us